AWARD-4 by Jendle et al. applied CGMS to 144 patients with T2DM by dulaglutide or glargine combined with insulin lispro and found that the SD of the dulaglutide group decreased significantly than that of the glargine group after being treated for 26 weeks and the intergroup difference had statistical significance. The gene discussed is INS; the disease is type 2 diabetes mellitus.